Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4
Status:
Completed
Trial end date:
2017-05-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or
without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.